Key Highlights Hims & Hers unveils Q2 financial results following today’s market close on August 10 Analyst projections call for a $0.05 per share deficit alongside approximately $698.9 milli
Hims & Hers Health unveils its second-quarter 2026 financial performance following today’s closing bell, with market participants intensely focused on whether the company’s strategic shift from compounded to branded GLP-1 pharmaceuticals is beginning to generate tangible results.
Hims & Hers Health, Inc., HIMS
Shares currently hover near $31.59, positioning the telehealth provider at a $7.3 billion market valuation. The equity has experienced significant turbulence across the trailing twelve months, oscillating between a floor of $13.74 and a ceiling of $65.30.
Financial analysts project a deficit of $0.05 per share accompanied by approximately $698.9 million in top-line revenue. This would represent a 28% year-over-year advancement and a meaningful improvement from Q1, when HIMS delivered a $0.40 per share shortfall on $608 million in sales, falling short of market forecasts.
The first-quarter disappointment was primarily attributed to expenses associated with the company’s March transition away from more affordable compounded GLP-1 offerings. Earnings per share projections have subsequently climbed 44% during the past sixty days, though revenue forecasts have remained unchanged.
Truist analyst Jailendra Singh maintained a Hold stance with a $27 valuation target before today’s disclosure. Singh indicated that Truist’s July transaction data implies HIMS is “well-positioned to exceed the high end of its Q2 revenue guidance,” with GLP-1 medications serving as the principal catalyst.
Singh additionally highlighted a consecutive deceleration in GLP-1 expansion entering July. GLP-1 billings on a daily basis declined 1% month-over-month in July following 32% expansion in June. The non-GLP-1 segment, conversely, demonstrated enhancement.
That July moderation might prompt leadership to exercise prudence when providing forward guidance, Singh observed. Nevertheless, he anticipates the organization will elevate its full-year 2026 projections to incorporate contributions from the Eucalyptus acquisition, which is forecast to contribute $450 to $500 million in annualized recurring revenue.
Customer persistence rates on branded oral Wegovy represent one of the critical benchmarks investors are monitoring. BofA Securities cautioned that retention “could be softer than some expect,” referencing rival Ro, which introduced oral Wegovy sooner and is currently experiencing diminishing new customer acquisitions and a stagnating subscriber foundation.
BofA further warned that attrition could escalate as subscription pricing advances from $39 during the initial month to $149 in following months.
Truist intelligence presents a moderately contrasting narrative. It demonstrates HIMS continues acquiring branded GLP-1 subscribers at a pace exceeding losses, and renewal subscribers currently constitute an expanding portion of the branded foundation. Singh stated this composition transformation is likely propelling the EBITDA margin enhancement the company anticipates during the latter half of 2026.
In July, the FDA’s Pharmacy Compounding Advisory Committee voted 8-6 to endorse BPC-157 for incorporation on the compounding registry, with KPV obtaining a comparable outcome. Canaccord characterized the development as “unambiguously positive,” though analysts indicated any meaningful revenue contribution from peptides remains improbable before 2028.
The derivatives marketplace is pricing in a 14.5% movement in either direction upon result publication. Wall Street’s prevailing consensus stands at Moderate Buy, derived from four Buy ratings and eight Hold ratings, featuring a mean valuation target of $30.65.
HIMS stock has declined 3% year-to-date.
The post Hims & Hers (HIMS) Q2 Earnings Preview: GLP-1 Transition Under the Microscope appeared first on Blockonomi.
